Wells Fargo lowered the firm’s price target on Merus (MRUS) to $89 from $91 and keeps an Overweight rating on the shares. The firm says there was not much new on the PR as the company continues to execute on its petosemtamab studies. Wells sees the ASCO update in first-line HNSCC and the mCRC update in the second half of 2025 for petosemtamab as the key catalysts in the next 12 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus’s Promising Clinical Data and Market Positioning Drive Buy Rating
- Promising Outlook for Merus: Buy Rating Backed by Petosemtamab’s Potential and Strong Financial Position
- Merus’s Strategic Advances and Market Opportunities Underpin Buy Rating
- Promising Growth Trajectory for Merus: Buy Rating Supported by Clinical Progress and Strategic Management
- Buy Rating Affirmed for Merus: Petosemtamab’s Potential in Metastatic HNSCC Market Despite Keytruda’s Perioperative Success